Joshua Ferrell
About Joshua Ferrell
Joshua Ferrell is a Principal Associate Scientist at ElevateBio, specializing in TCR and CAR discovery. He holds a Master's Degree in Medical Sciences from the University of Kentucky and has extensive experience in molecular and cellular biology.
Current Role at ElevateBio
Joshua Ferrell serves as a Principal Associate Scientist at ElevateBio, a position he has held since 2022. In this role, he focuses on advancing research and development in the field of cellular and molecular biology. His expertise in T-cell receptor (TCR) and chimeric antigen receptor (CAR) discovery contributes to the company's mission of developing innovative cell and gene therapies.
Previous Experience at ElevateBio
Prior to his current role, Joshua Ferrell worked at ElevateBio as a Senior Associate Scientist from 2020 to 2022. During this time, he contributed to various projects that aimed to enhance the understanding and application of cellular therapies. His experience at ElevateBio has allowed him to deepen his knowledge in the field.
Educational Background
Joshua Ferrell earned a Master’s Degree in Medical Sciences from the University of Kentucky, where he studied from 2013 to 2017. He also holds a Bachelor’s Degree in Biology/Biological Sciences from Morehead State University, which he completed from 2009 to 2013. His academic background provides a strong foundation for his work in molecular and cellular biology.
Research Experience
Joshua Ferrell has a diverse research background, having worked as a Research Assistant at the University of Kentucky from 2013 to 2017. He also served as an Undergraduate Research Fellow at Morehead State University from 2012 to 2013. His experience includes roles as a Molecular Biologist at Aegis Sciences Corporation and various positions at bluebird bio, where he focused on TCR and CAR discovery.
Specialization in Molecular Biology
Joshua Ferrell specializes in TCR and CAR discovery, with a strong emphasis on molecular and cellular biology. His expertise in these areas is critical for the development of advanced therapeutic strategies. His work has implications for improving treatment options in immunotherapy and related fields.